Follow our journey: cureblausyndrome

Contact us: info@curebs.com

  • Facebook
  • Twitter
  • Instagram

  Mail: Cure Blau Syndrome Foundation 1138 Old Esquimalt Rd.   Victoria, BC  Canada V9A4X6

wouters.jpg

Carine H Wouters is a pediatric rheumatologist working at Leuven University Hospital in Leuven, Belgium.

She is head of the clinical department of pediatric rheumatology and immune-inflammatory diseases at the Leuven University Children’s hospital, and professor in Pediatrics at Leuven University. She currently is the chair for clinical affairs in the PReS council.

Her major research interests comprise systemic juvenile idiopathic arthritis and macrophage activation syndrome (in collaboration with research group of Immunobiology, Patrick Matthys, Leuven), autoinflammatory diseases (in collaboration with research group Genetics of Autoimmunity, Adrian Liston)  as well as granulomatous inflammatory diseases in children with a special interest to Blau syndrome (in collaboration with Carlos Rose, Wilmington, US).

Medical Advisory Board Member

Carine Wouters, M.D., Ph.D.

Carlos Rose.jpg

Information coming soon.

Medical Advisory Board Member

Carlos Rose, M.D.

Dr. Napier is the principal investigator of a translational immunology laboratory at the VA Portland Health Care System and Oregon Health & Science University in Portland, OR. She has extensive experience in basic and clinical research in the fields of microbiology, immunology, autoimmunity, inflammation, and drug development.

 

Dr. Napier received her PhD from Emory University in Atlanta, GA where she repurposed a previously FDA-approved cancer drug as a novel immunotherapy to treat tuberculosis, which is currently in a Phase II clinical trial. She then completed two postdoctoral fellowships at Oregon Health & Science University in the Departments of Pulmonary and Critical Care Medicine and Molecular Microbiology and Immunology. Dr. Napier’s research program is focused on understanding how microbial sensors, including the gene NOD2 (which is linked to Blau Syndrome), control pathogenic cellular responses in autoimmune and autoinflammatory diseases such as autoimmune arthritis and uveitis, Blau Syndrome, and Yao Syndrome.

 

Her long-term research goal is to use this information towards discovery of biomarkers associated with hard-to-diagnose inflammatory diseases, and development of novel biologics that aim to reprogram pathogenic immune cells back to a quiescent state and thereby thwart progression of disease.

Medical Advisory Board Member

Ruth Napier, Ph.D.